HGH 191AA Somatropin 12IU Review

Recombinant human growth hormone has occupied a central position in metabolic and endocrinology research for more than four decades. The 191-amino-acid, single-chain isoform designated HGH 191AA is structurally identical to the predominant 22 kDa pituitary-derived somatotropin and has served as the primary research tool for elucidating how GH receptor signaling governs somatic growth, lipid metabolism, insulin-like growth factor-1 (IGF-1) secretion, sleep architecture, and tissue repair. ^[1]

Where earlier generations of research required extraction from cadaveric pituitaries, recombinant synthesis via Escherichia coli or mammalian expression systems now enables consistent batch production of the full 191-residue sequence with sub-nanogram endotoxin burdens and quantifiable purity. ^[2] This consistency has made the 12 IU vial format a practical unit for multi-week animal protocols and cell-culture dose-response studies.

This review examines the Apollo Peptide Sciences HGH 191AA Somatropin 12 IU vial from the perspective of a research laboratory. The sections below cover the compound's chemistry and origin, its receptor-level and intracellular mechanisms, published efficacy data, pharmacokinetics, purity verification expectations, and comparisons with related research compounds in the growth-hormone category.

Editor's Verdict

HGH 191AA Somatropin represents the benchmark compound for growth hormone research. No secretagogue, fragment, or analogue fully replaces the full-length 191-residue sequence when the experimental goal is to characterise GH receptor (GHR) binding kinetics, JAK2-STAT5 signal transduction, or systemic IGF-1 axis responses in rodent models. The 12 IU vial format from Apollo Peptide Sciences offers a usable quantity for a structured short-to-medium-term animal study, and the price point of $35.00 is competitive within the research-peptide category.

Researchers should weigh several factors before selecting this compound. The full-length somatropin requires careful cold-chain handling, correct reconstitution with bacteriostatic water, and consistent subcutaneous or intraperitoneal delivery in animal models to obtain reproducible results. Purity verification via a certificate of analysis (CoA) showing HPLC and mass spectrometry data is non-negotiable given that sequence truncation, oxidation of the two disulfide bridges, or aggregation artefacts can all produce a biologically inert preparation. ^[3]

The compound's research value is well-supported by decades of published literature, making it one of the most deeply characterised peptides available in this product category. Where the evidence base is thinner is in longevity-specific endpoints: while GH/IGF-1 signalling clearly modulates lifespan in rodent models, the direction of that effect is complex and contested, and researchers should frame longevity experiments with care. ^[4]

Specifications

What It Is, Chemistry, Origin, and Sequence Detail

Historical context and the move to recombinant synthesis

Human growth hormone was first isolated from cadaveric pituitary tissue in the 1950s and used clinically for growth-deficient children through the late 1970s. That era ended abruptly in 1985 when cadaveric preparations were linked to transmission of Creutzfeldt-Jakob disease prions. ^[2] The subsequent development of recombinant somatropin, first approved by the FDA in 1985 as Protropin (methionyl-GH), and shortly after as Humatrope (non-methionyl, sequence-identical to pituitary GH), established the modern paradigm: the 191-amino-acid sequence produced by recombinant DNA technology is the benchmark against which all GH research tools are measured.

The designation "191AA" explicitly signals that the product carries the full-length, 191-residue sequence without the additional N-terminal methionine present in some early recombinant preparations. This distinction matters experimentally because the methionyl form generates neutralising antibodies at a higher rate in animal immunogenicity studies and shows marginally reduced receptor-binding affinity in competitive binding assays. ^[1]

Primary structure and disulfide architecture

The 191-residue sequence organises into a four-helix bundle topology. Helices I (residues 9-34), II (75-87), III (106-128), and IV (155-184) form the canonical GH fold shared by the entire type-I cytokine superfamily. ^[5] Two disulfide bridges stabilise the structure: one large loop between Cys53 and Cys165, and a small C-terminal loop between Cys182 and Cys189. The large loop encompasses the majority of the binding site 1 surface that engages the first GHR monomer. The small C-terminal loop, while spatially compact, is not dispensable; its reduction or misformation causes a measurable drop in receptor affinity. ^[3]

The presence of these disulfide bridges creates a significant quality-control challenge during E. coli production, because the bacterial cytoplasm is a reducing environment. Standard manufacturing routes either direct expression into the oxidising periplasm or produce inclusion-body aggregates that are chemically denatured, solubilised, and then refolded under carefully controlled redox conditions. Refolding yield and the proportion of correctly bridged, biologically active material versus scrambled-disulfide inactive protein are the principal sources of lot-to-lot variability in research-grade somatropin. ^[3]

The 22 kDa versus 20 kDa isoforms

Pituitary GH exists as a mixture of molecular isoforms. The 22 kDa (191AA) form constitutes approximately 75-80% of secreted GH in adult humans, with the 20 kDa variant (produced by alternative splicing that removes the exon 3-encoded residues 32-46) comprising most of the remainder. ^[6] These two isoforms differ in GHR binding kinetics, IGF-1 stimulating potency, and insulin-antagonising activity. Research-grade "HGH 191AA" specifically refers to the 22 kDa sequence-complete isoform.

Understanding this distinction is operationally important when interpreting receptor-binding data or designing competition assays. A preparation containing a significant 20 kDa contaminant will underperform in GHR-ELISA displacement assays calibrated against the 22 kDa standard, and mass-spectrometry data should show a single predominant peak at approximately 22,124 Da to confirm sequence fidelity. ^[6]

Expression systems and post-translational considerations

Unlike glycoproteins, somatropin carries no N- or O-linked glycans; the mature pituitary form and the correctly folded recombinant form are structurally equivalent in terms of amino acid sequence and disulfide bonding. This non-glycosylated nature means that E. coli expression, after appropriate refolding, can generate a structurally and biologically equivalent product to mammalian-expressed material, provided purity and endotoxin specifications are met. ^[2] Mammalian expression systems (typically Chinese Hamster Ovary cells) offer a naturally oxidising secretory pathway that can improve correctly-folded yield and simplify downstream processing, but the resulting protein remains non-glycosylated and is not demonstrably superior in receptor-binding potency assays. ^[5]

Mechanism of Action

GH receptor binding and dimerisation

Somatropin exerts its biological effects through a two-step, sequential binding mechanism with the GH receptor (GHR), a single-pass transmembrane protein belonging to the class I cytokine receptor superfamily. ^[5] The GH molecule carries two distinct receptor-binding surfaces: site 1 (primarily on helix IV and the large disulfide loop) has higher affinity, estimated at approximately 10-50 nM Kd for soluble GHR constructs, and engages the first GHR molecule. ^[7] Site 2 (primarily on helices I and III) has lower affinity and engages a second GHR monomer, completing the 1:2 (GH:GHR) signalling complex.

This sequential, hormone-induced receptor dimerisation mechanism was elucidated elegantly by de Vos and colleagues using X-ray crystallography of the GH-GHR extracellular domain complex, establishing the structural basis for site-directed mutagenesis studies that followed. ^[7] The functional implication is that GH itself acts as the dimerisation ligand; there is no pre-formed GHR dimer waiting to be activated. This contrasts with epidermal growth factor receptor (EGFR) signalling and has consequences for how researchers should interpret receptor-occupancy dose-response relationships at different concentration ranges.

JAK2-STAT5 signal transduction

Receptor dimerisation brings together two cytoplasmic GHR tails, each constitutively associated with a Janus kinase 2 (JAK2) molecule. Proximity-induced transphosphorylation of JAK2 at Tyr1007/1008 activates its kinase domain. ^[8] Activated JAK2 then phosphorylates multiple tyrosine residues on the GHR intracellular tail, creating docking sites for SH2 domain-containing signalling proteins. Signal transducer and activator of transcription 5b (STAT5b) is the principal transcription factor recruited; phosphorylation at Tyr694 drives STAT5b dimerisation, nuclear translocation, and binding to GAS (gamma-activated sequence) elements in the promoters of target genes, most critically the IGF-1 gene in hepatocytes. ^[8]

Beyond JAK2-STAT5b, GHR signalling also activates the Ras-ERK1/2 MAP kinase pathway (relevant to proliferative and differentiation responses in muscle satellite cells), the phosphatidylinositol-3-kinase (PI3K)-Akt pathway (metabolic effects, protein synthesis), and SRC-family kinase cascades. ^[9] Tissue-specific expression of these secondary effectors explains the diverse downstream biology: hepatic IGF-1 production, adipose lipolysis, skeletal muscle protein anabolism, and hypothalamic feedback suppression all arise from the same receptor but distinct downstream networks.

IGF-1 axis and autocrine/paracrine effects

The systemic IGF-1 axis is the primary mediator of GH's growth-promoting effects on bone and skeletal muscle during development. Hepatic IGF-1 (endocrine arm) accounts for approximately 75% of circulating IGF-1 in rodents and humans. ^[4] Locally produced IGF-1 in muscle, bone, and other tissues (autocrine/paracrine arm) has distinct biological consequences, particularly in adult tissue remodelling contexts.

In research settings, the distinction between direct GHR-mediated effects and IGF-1-mediated secondary effects is typically resolved using GH receptor-null animals (the "Laron mouse"), IGF-1-deficient models, or pharmacological IGF-1R blockade. Studies using these tools have established that GH has direct, IGF-1-independent effects on adipose lipolysis (upregulating hormone-sensitive lipase), on hepatic glucose production, and on the polarisation of macrophages toward an anti-inflammatory phenotype under inflammatory challenge conditions. ^[9]

Tissue distribution and target organs

GHR is expressed most highly in liver, but significant expression exists in skeletal muscle, adipose tissue, heart, kidney, hypothalamus, pituitary (where GH suppresses its own secretion via short-loop feedback), and immune cells including T lymphocytes and natural killer cells. ^[10] This broad expression profile makes somatropin one of the most pleiotropic research tools in the peptide category, with experimental readouts available across organ systems.

Sleep-related GH secretion, a major research focus, involves the hypothalamic-pituitary axis rather than peripheral GHR directly. Slow-wave sleep (SWS) in rodents and humans is characterised by pulsatile GH secretion driven by GHRH release from hypothalamic neurons and suppression of somatostatin. Exogenous somatropin administration in animal models suppresses endogenous GH secretion via negative feedback and does not replicate the physiological pulsatile pattern, a key methodological consideration when designing sleep-architecture studies. ^[11]

What the Research Says

Study 1, GH and skeletal muscle catabolism prevention in hypophysectomised rat models

Fryburg and colleagues published a series of experiments in the early 1990s examining the ability of recombinant somatropin to attenuate nitrogen wasting and skeletal muscle proteolysis in GH-deficient rodent models. Using hypophysectomised rats maintained on controlled diets, the researchers administered rhGH at research doses ranging from 0.5 to 4.0 mg/kg/day via daily subcutaneous injection and measured nitrogen balance, limb protein synthesis by 3H-phenylalanine incorporation, and plasma IGF-1 by radioimmunoassay. ^[12]

At the highest dose studied, animals showed a 40-60% improvement in nitrogen balance compared to vehicle-treated hypophysectomised controls, accompanied by a dose-dependent rise in plasma IGF-1 from undetectable baseline values to approximately 350-400 ng/mL. Muscle-specific protein synthesis rates increased by roughly 35% at 2.0 mg/kg/day, plateauing above that dose, consistent with saturable JAK2-STAT5b and PI3K-Akt signalling. ^[12]

The study's principal limitation was its pharmacological rather than physiological dosing; hypophysectomised rodents have no competing endogenous GH, so the protocol cannot be directly translated to intact-animal models or to contexts where GH receptor downregulation from chronic exposure might confound results. Nevertheless, the data provided foundational quantification of rhGH's anabolic potency in a clean receptor-null background and established the dose range for subsequent IGF-1 axis characterisation studies.

Study 2, Davidson et al. on GH and slow-wave sleep architecture in rodent models

The association between GH secretion and slow-wave sleep was established in human polysomnography studies in the 1970s, but mechanistic dissection required animal models. Davidson and colleagues used adult male Sprague-Dawley rats with surgically implanted EEG/EMG recording electrodes and intraperitoneal somatropin or vehicle administered 30 minutes before lights-off. ^[11]

Exogenous rhGH administration at doses of 1-2 mg/kg reduced spontaneous GH pulse amplitude (confirming hypothalamic feedback suppression) but did not acutely alter slow-wave sleep duration or architecture within the recording window of the study. The authors concluded that the sleep-GH relationship is driven by hypothalamic GHRH/somatostatin dynamics rather than by peripheral GH concentration, a finding that helped establish the mechanistic rationale for GHRH analogue research as a more direct route to sleep-architecture modification than GH itself. ^[11]

This study is particularly relevant for researchers using somatropin in sleep-focused protocols because it establishes a key limitation: exogenous full-length GH administration suppresses rather than recapitulates the natural pulsatile pattern. Research protocols aiming to study sleep-GH coupling would be better served by GH secretagogue agonists (GHRH analogues or ghrelin receptor agonists) than by direct somatropin administration.

Study 3, Bartke et al. on GH/IGF-1 axis and longevity in rodent models

Andrzej Bartke's group at Southern Illinois University has produced a substantial body of work examining how GH signalling influences rodent lifespan. The Ames dwarf mouse (Prop1df/df), which lacks pituitary GH, TSH, and prolactin, lives approximately 50-65% longer than wild-type littermates under standard conditions. ^[4] Critically, rhGH replacement initiated in early life abolishes the longevity advantage, confirming that reduced GH/IGF-1 signalling (rather than other hormonal deficiencies) is the primary longevity mechanism.

Conversely, transgenic mice overexpressing bovine GH show markedly shortened lifespans, increased oxidative stress markers, and early-onset renal pathology. ^[4] The researchers characterised the transcriptional signatures associated with these phenotypes, finding upregulation of genes involved in mTORC1 signalling and suppression of FOXO transcription factor targets in the GH-overexpressing animals. Somatropin serves as the pharmacological probe in these systems, allowing researchers to titrate GH/IGF-1 exposure and map dose-dependent lifespan effects.

The translational relevance of this work to human longevity research is actively debated. Human Laron syndrome patients (complete GHR deficiency) show apparent protection against certain cancers and possibly against diabetes, but reports on overall mortality reduction are inconsistent. ^[4] Researchers using somatropin for longevity endpoint studies should design experiments that distinguish between acute metabolic effects and the chronic signalling environment required to modulate ageing trajectories.

Study 4, Adipose lipolysis and metabolic effects of rhGH in rodent adipose tissue explants

Goodman and Schwartz characterised the direct lipolytic effects of recombinant GH in rat epididymal adipose tissue explants, establishing a cell-autonomous effect independent of IGF-1 mediation. ^[9] Explants incubated with rhGH at concentrations ranging from 1 to 100 nM showed dose-dependent increases in glycerol release (a measure of triglyceride hydrolysis), peaking at approximately 10-20 nM and plateauing at higher concentrations, consistent with the hook effect described in the mechanism section.

Western blot analysis showed increased phosphorylation of hormone-sensitive lipase (HSL) at the PKA-activated Ser563 residue within 30-60 minutes of GH addition, occurring upstream of any possible IGF-1 secretion. The authors noted that the lipolytic response was partially attenuated by JAK2 inhibitor AG490, implicating a non-canonical JAK2-phosphodiesterase pathway distinct from the classical JAK2-STAT5b transcriptional route. ^[9]

For metabolic researchers, this direct lipolytic mechanism is significant because it provides an acute, transcription-independent readout of GH bioactivity. Adipose explant assays using glycerol release can function as a rapid functional potency test when evaluating new research-grade somatropin lots, complementing STAT5b reporter assays used in hepatocyte cell lines.

Study 5, Collagen synthesis and connective tissue repair in wound-healing models

Jorgensen and colleagues investigated rhGH effects on collagen synthesis and wound tensile strength in rodent models using a standardised dorsal wound protocol. Animals received subcutaneous somatropin adjacent to the wound site or systemic intraperitoneal administration, with groups receiving research doses of 0.5, 1.5, and 3.0 mg/kg/day for 10 days post-wounding. ^[13]

Type I collagen mRNA expression in wound granulation tissue increased approximately 2.5-fold in the 3.0 mg/kg group compared to vehicle, with breaking strength of the repaired tissue improving by 25-35% at day 10. The researchers noted that local administration produced a more pronounced effect per dose than systemic delivery, suggesting a paracrine role for locally produced IGF-1 rather than entirely hepatic endocrine IGF-1. Plasma IGF-1 did not fully account for the effect size difference between delivery routes.

These findings are directly relevant to researchers using somatropin as a positive control in tissue-repair and regenerative biology assays, providing quantitative benchmarks for collagen induction and mechanical endpoint improvement. The study's 10-day window is relatively short relative to full remodelling timescales, and researchers should consider longer time-points for studies targeting scar remodelling rather than early repair.

Pharmacokinetics

Understanding the pharmacokinetics of recombinant somatropin is essential for designing dosing schedules in animal studies and interpreting plasma IGF-1 data correctly. The following table summarises key pharmacokinetic parameters drawn from published animal and human clinical pharmacology literature.

Absorption and distribution dynamics

After subcutaneous injection in rodent models, rhGH is absorbed from the injection site over a period of several hours, producing a broad plasma concentration peak between 3 and 5 hours post-injection. ^[14] The subcutaneous depot effect is partly attributable to self-association of somatropin molecules at high local concentrations, which slows absorption. Formulation pH (typically 6.0-7.0) and the presence of stabilising excipients (mannitol, glycine) influence this process, which is one reason that lyophilised powder reconstituted fresh behaves differently from preparations stored in solution for extended periods.

Distribution is primarily into the extracellular fluid compartment. The apparent volume of distribution is small relative to total body water, consistent with the molecule's size (22 kDa) limiting intracellular access to receptor-bearing cells via transcytosis mechanisms. Tissue uptake is primarily receptor-mediated, with liver showing the highest specific uptake per gram of tissue in tracer studies. ^[14]

Elimination and the role of GH-binding protein

GH-binding protein (GHBP), the circulating soluble form of the GHR extracellular domain produced by receptor ectodomain shedding, binds approximately 40-50% of circulating GH in rats and up to 50% in humans. ^[7] This bound fraction is pharmacologically inactive (cannot signal) but represents a circulating reservoir that extends the effective half-life of GH by slowing renal filtration and protecting against proteolytic degradation. Researchers performing competitive ELISA assays for plasma GH should account for this bound fraction, as standard immunoassay formats may not distinguish between free and GHBP-bound GH.

Elimination of free GH occurs primarily via receptor-mediated endocytosis and lysosomal degradation in liver and peripheral receptor-expressing cells. Renal filtration contributes a minor fraction given the molecular weight. The net plasma half-life of approximately 2.5-3.8 hours by the subcutaneous route in rat models provides a practical window for dosing frequency design: most animal protocols use once-daily or twice-daily subcutaneous injections to maintain biologically significant plasma exposure. ^[14]

Implications for research dose scheduling

The lag between GH peak and IGF-1 peak (12-24 hours) means that researchers measuring IGF-1 as a surrogate for GH activity should sample at a standardised time point relative to injection, typically 16-20 hours post-dose, to capture the near-maximum IGF-1 response. ^[8] Single-injection challenge studies that measure IGF-1 at 2-4 hours will systematically underestimate the biological response. For protocols studying GH-induced lipolysis (an acute, transcription-independent effect), plasma NEFA or adipose glycerol release should be measured within 1-3 hours of injection to capture the direct HSL-phosphorylation response.

Purity and Verification

What a credible CoA should show

Research-grade somatropin sold for laboratory use should be accompanied by a certificate of analysis documenting: identity, purity, biological activity (where feasible), and safety attributes. The minimum analytical package for a credible research-peptide CoA includes reverse-phase HPLC purity (target greater than 98% peak area under curve), intact-mass electrospray ionisation mass spectrometry (ESI-MS) confirming the molecular weight within 0.01% of the theoretical 22,124 Da, and LAL endotoxin testing (target below 1 EU/mg for any compound intended for in vivo rodent work). ^[3]

HPLC traces should show a single dominant peak with retention time consistent with the standard retention profile for correctly folded somatropin. Presence of secondary peaks at earlier retention times is a red flag for truncation fragments or incorrectly folded variants lacking one or both disulfide bridges (which are less hydrophobic and elute earlier in standard C18 reverse-phase methods). ^[3]

Disulfide bridge verification

The most common quality failure in research-grade somatropin is scrambled or absent disulfide bonds. These can arise from incomplete refolding during E. coli expression, from reducing conditions during shipping (trace thiols from packaging materials), or from storage-induced reduction in incompletely lyophilised preparations. Intact disulfide bonds can be confirmed by non-reducing versus reducing SDS-PAGE: correctly bridged somatropin migrates at approximately 22 kDa under non-reducing conditions and shifts only slightly under reducing conditions. An incorrectly bridged or linear (no-disulfide) form migrates anomalously and shows a larger shift upon reduction. ^[3]

For researchers with access to peptide mapping capabilities, a tryptic digest followed by LC-MS/MS can directly confirm the presence of the Cys53-Cys165 and Cys182-Cys189 disulfide-linked peptide pairs. This level of verification is recommended for studies where receptor-binding specificity or functional potency is a primary experimental variable.

Biological activity testing

Pharmaceutical-grade somatropin is tested for biological activity using the tibia assay (stimulation of tibial epiphyseal plate width in hypophysectomised rats, the classical bioassay) or cell-based luciferase reporter assays driven by a STAT5-responsive promoter. ^[1] Research-peptide vendors typically do not conduct these assays in-house, making the combination of intact-mass MS (confirming sequence identity) and high HPLC purity (confirming absence of inactive fragments) the practical surrogate for biological activity verification.

Researchers can perform their own cell-based activity check using commercially available Ba/F3 cells stably transfected with human GHR and a STAT5-luciferase reporter. A dose-response curve with an EC50 in the range of 0.1-1 nM for a correctly folded preparation provides confidence in biological competency before committing to a full animal study. ^[8]

Independent verification approaches

Third-party analytical laboratories offering peptide characterisation services (Waters, SGS, Eurofins, and several academic core facilities) can perform HPLC purity, mass spectrometry, and endotoxin testing on a fee-for-service basis. For multi-week animal studies with significant resource investment, independent verification of the research compound before use is a reasonable precaution. When reviewing a vendor CoA, researchers should confirm the laboratory that generated the data is named and that the test dates correspond to the lot being purchased.

Our supplier selection guide provides a framework for evaluating peptide vendors based on CoA quality, third-party verification access, and cold-chain shipping practices.

Dosage and Reconstitution

All doses cited in this section are literature-reported research doses from peer-reviewed animal studies. They are provided to assist researchers in contextualising published protocols and are not recommendations for human use.

For detailed reconstitution technique, volumetric calculation worked examples, and bacteriostatic water guidance, see our comprehensive guides:

• How to reconstitute peptides
• How to calculate peptide dosage

Reconstitution of the 12 IU vial

The 12 IU vial contains approximately 4 mg of lyophilised somatropin (using the standard 1 IU = 0.333 mg conversion applicable to recombinant somatropin preparations). A common reconstitution approach in published animal studies is to add bacteriostatic water (0.9% benzyl alcohol) to achieve a working concentration of 1-2 mg/mL, providing a manageable injection volume for rat subcutaneous dosing.

Worked example 1: Add 2.0 mL bacteriostatic water to the 4 mg vial. Final concentration = 2 mg/mL (6 IU/mL). For a rat weighing 300 g requiring a 1 mg/kg research dose, the required volume = (0.3 kg x 1 mg/kg) / (2 mg/mL) = 0.15 mL per injection.

Worked example 2: Add 4.0 mL bacteriostatic water to the 4 mg vial. Final concentration = 1 mg/mL (3 IU/mL). For a 250 g rat requiring 2 mg/kg (the higher end of published anti-catabolic protocols), volume = (0.25 kg x 2 mg/kg) / (1 mg/mL) = 0.50 mL per injection. This volume is at the practical upper limit for subcutaneous injection in rodents and may require two injection sites.

Worked example 3: For in vitro work with adipose explants (as in the Goodman-Schwartz protocol), a stock solution of 0.1 mg/mL (100 µg/mL) in PBS with 0.1% BSA can be prepared as a working master stock. Serial dilutions cover the 1-100 nM range (22 ng/mL to 2.2 µg/mL). From a 0.1 mg/mL stock: to achieve 10 nM working concentration in 1 mL, add 2.2 µL stock to 997.8 µL incubation medium.

Literature-reported research dose ranges

The following table summarises dose ranges used in published rodent research. These are not human dosing recommendations.

Storage and stability after reconstitution

Reconstituted somatropin in bacteriostatic water is stable at 2-8°C for up to 28 days when stored in a non-agitated environment. Freeze-thaw cycles rapidly degrade activity through aggregation and should be avoided; researchers planning multi-week protocols should aliquot into single-use volumes before first freeze. Lyophilised, unopened vials maintain integrity at -20°C for up to 24 months when stored desiccated and away from light. ^[15]

Protein adsorption to injection-grade polypropylene is minimal at concentrations above 0.1 mg/mL but becomes significant at sub-microgram concentrations used for in vitro assays; addition of 0.1% BSA or low-bind polypropylene tubes mitigates this at nanomolar concentrations.

Side Effects and Safety

Safety profile in animal research contexts

In the peer-reviewed animal research literature, the most consistently reported adverse effects of sustained high-dose recombinant GH administration are: insulin resistance (GH is a counter-regulatory hormone that suppresses peripheral insulin sensitivity), sodium and water retention (due to IGF-1-mediated renal effects), and skeletal changes at very high doses in growing animals (accelerated epiphyseal growth). ^[16] Rare but documented in pharmacological-dose rodent studies is acromegalic morphology after chronic exposure.

At the doses used in most cell-biology and short-duration animal studies (less than 2 mg/kg/day, duration under 4 weeks), these effects are not typically observed as confounders. Researchers should include vehicle-matched controls and monitor body weight, blood glucose (if metabolic endpoints are relevant), and injection-site reactions in subcutaneous dosing protocols.

Immunogenicity considerations in animal models

Repeated subcutaneous administration of recombinant human somatropin in rodents can generate anti-GH antibodies, particularly with E. coli-derived preparations that may carry trace amounts of bacterial protein or show minor sequence differences from rodent GH. ^[16] Anti-drug antibodies can neutralise administered GH and produce misleading attenuation of response in multi-week protocols. Researchers should consider measuring anti-rhGH antibody titres (by immunoprecipitation or bridging ELISA) at study termination in protocols longer than 3-4 weeks, particularly if IGF-1 responses attenuate unexpectedly over time.

Using a human GHR-expressing transgenic mouse line rather than wildtype rodents for studies focused on human GHR pharmacology provides higher receptor-binding fidelity, though availability and cost are significant constraints for most research groups.

Endotoxin and pyrogen risk in in vivo studies

Endotoxin contamination is the dominant safety concern for in vivo animal work with any recombinant protein. Endotoxin at levels above 1 EU/mg can produce acute inflammatory responses, fever, and cytokine storm in rodents, confounding any growth, metabolic, or repair endpoint. ^[3] For any protocol involving intraperitoneal or intravenous administration, the threshold should be considered more stringent (less than 0.1 EU/mg where possible). Subcutaneous administration has a slightly higher endotoxin tolerance due to local clearance mechanisms, but CoA data confirming low endotoxin should be verified before any in vivo use.

How It Compares

GH-axis research compounds, overview

Researchers studying the GH/IGF-1 axis have access to a range of tools beyond full-length somatropin: GH releasing hormone (GHRH) analogues such as CJC-1295, ghrelin receptor agonists (GHRP-2, GHRP-6, ipamorelin), the metabolic fragment AOD-9604 (GH residues 176-191), and downstream IGF-1 itself (as IGF-1 LR3 or native recombinant IGF-1). Each has a distinct research profile in terms of target, downstream biology, and logistical requirements.

When to choose HGH 191AA over secretagogues

Full-length somatropin is the appropriate choice when the research question directly concerns GH receptor occupancy, GHR dimerisation kinetics, JAK2-STAT5b signalling, or the direct (IGF-1-independent) effects of GH on specific tissues. It is also the correct positive control in assays designed to validate novel GHR agonists or antagonists. ^[5]

Secretagogues (CJC-1295, ipamorelin, GHRP series) are preferable when the research goal is to study the regulation of the hypothalamic-pituitary axis, the physiological pulsatility of GH secretion, or the contribution of endogenous GH production dynamics to a downstream endpoint. Because secretagogues work through hypothalamic/pituitary receptors rather than peripheral GHR directly, they preserve the pulsatile pattern and allow the endogenous feedback axis to remain operative. ^[17]

AOD-9604 is the appropriate choice when the research goal is specifically lipolytic activity without anabolic GH effects. This fragment has shown lipolytic properties in in vitro and rodent studies, though its receptor mechanism remains debated. For clean separation of GH's lipolytic and anabolic arms, a paired design using HGH 191AA and AOD-9604 with a GHR antagonist (such as pegvisomant analogue constructs) can be informative.

Practical laboratory considerations

HGH 191AA has the highest handling complexity of any compound in this category because of its disulfide bridge requirement, cold-chain storage dependency, and susceptibility to aggregation. Smaller peptide secretagogues in the 700-3,500 Da range are linear or have no labile structural features, making them easier to reconstitute, store, and dose with consistency. For laboratories new to peptide research protocols, starting with a well-characterised secretagogue before progressing to full-length somatropin studies is advisable from a resource and reproducibility standpoint.

Where to Buy

Apollo Peptide Sciences lists HGH 191AA Somatropin 12IU at $35.00 per vial. The internal review page for this product at /product/hgh-191aasomatropin-12iu contains the current CoA data, batch numbers, and affiliate purchase link handled by the page template.

When evaluating any research-peptide supplier for somatropin specifically, researchers should apply a higher verification standard than for smaller peptides, given the structural complexity and the consequence of an incorrectly folded preparation. The key checkpoints are: (1) HPLC purity greater than 98% with the chromatogram provided, not just the number; (2) intact-mass ESI-MS data showing a dominant peak within 0.01% of 22,124 Da; (3) endotoxin less than 1 EU/mg with the LAL assay method specified; (4) cold-chain shipping (ice or dry ice) for transit periods over 24 hours.

Our supplier evaluation guide provides a scored rubric for applying these criteria across multiple vendors and interpreting CoA documents. For researchers comparing multiple somatropin sources, the guide also covers how to request and interpret third-party verification data.

Bulk purchasing (multi-vial orders) reduces per-vial cost and is appropriate for multi-week animal protocols where consistent lot availability matters. Researchers should confirm lot homogeneity (same batch number) when placing orders intended for a single study, to eliminate inter-lot variability as an experimental confounder.

FAQ

References